NeoGenomics appointed President and COO Warren Stone as Chief Executive Officer and Board member, effective January 4, 2027. Current CEO Tony Zook will transition to Executive Chairman at the same time. The Board also increased its size from ten to eleven directors, appointed Michael Kelly as Lead Independent Director, and noted that Chair Lynn Tetrault will step down as Chair but remain a director until the 2027 Annual Meeting, where she does not intend to stand for reelection. Concurrently, the company announced preliminary unaudited third quarter revenue of approximately $209 million, reflecting next-generation sequencing revenue growth of about 28%. NeoGenomics operates in the oncology diagnostics industry, providing cancer genetics testing and information services.
